The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...

The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...

The FDA suggests that prescribed users also reduce their calorie intake and increase their exercise The weight loss drug ...

The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...

called the FDA’s approval a "promising advancement for the millions of people who suffer from this condition." "Zepbound promotes weight loss and has been shown to reduce apnea events." ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

( NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea ...

Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.

which was approved for weight loss for those with obesity, or who are overweight and have a weight-related health condition, in November 2023.Although the new FDA green light doesn't expand the ...

The United States Food and Drug Administration (FDA) has approved the weight-loss drug Tirzepatide — sold by the brand name ...